ERBB2 and breast cancer: Early clinical studies have indicated that anti-HER2 therapy provides benefit exclusively to patients with breast cancer scoring 3+ at immunohistochemistry (IHC) and/or exhibiting gene amplification at in situ hybridization (ISH)1–3.